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Abstract
Human induced pluripotent stem cells (hiPSC) have been generated from different tissues, with the age of the donor, tissue
source and specific cell type influencing the reprogramming process. Reprogramming hematopoietic progenitors to hiPSC
may provide a very useful cellular system for modelling blood diseases. We report the generation and complete
characterization of hiPSCs from human neonatal fibroblasts and cord blood (CB)-derived CD34+ hematopoietic progenitors
using a single polycistronic lentiviral vector containing an excisable cassette encoding the four reprogramming factors Oct4,
Klf4, Sox2 and c-myc (OKSM). The ectopic expression of OKSM was fully silenced upon reprogramming in some hiPSC clones
and was not reactivated upon differentiation, whereas other hiPSC clones failed to silence the transgene expression,
independently of the cell type/tissue origin. When hiPSC were induced to differentiate towards hematopoietic and neural
lineages those hiPSC which had silenced OKSM ectopic expression displayed good hematopoietic and early neuroectoderm
differentiation potential. In contrast, those hiPSC which failed to switch off OKSM expression were unable to differentiate
towards either lineage, suggesting that the residual expression of the reprogramming factors functions as a developmental
brake impairing hiPSC differentiation. Successful adenovirus-based Cre-mediated excision of the provirus OKSM cassette in
CB-derived CD34+ hiPSC with residual transgene expression resulted in transgene-free hiPSC clones with significantly
improved differentiation capacity. Overall, our findings confirm that residual expression of reprogramming factors impairs
hiPSC differentiation.
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Introduction
Human fibroblasts were the first cell type successfully repro-
grammed by ectopic expression of OCT4, SOX2, KLF4 and c-
MYC (OKSM) [1,2,3,4,5,6]. Subsequently, human induced
pluripotent stem cells (iPSC) have been derived from different
tissues, and further studies have shown that the age, origin and cell
type used as target for reprogramming affects the reprogramming
efficiency, eventually requiring the expression of fewer factor
[7,8,9]. Cord blood (CB) represents a source enriched with
hematopoietic, mesenchymal and endothelial precursors. Access to
CB units is very feasible by harnessing those CB units which do not
reach the minimum quality criteria to be frozen and stored for
potential future use in CB allogeneic transplantation and would
otherwise be discarded at the public CB banks. Besides, CB cells
are young newborn cells expected to accumulate minimal somatic
mutations as compared to other somatic tissues sourced from older
subjects, and they display the immunological immaturity of
neonatal cells [10].
Recently, Haase et al [11] derived hiPSC from CB-derived
endothelial cells while Giorgetti et al [7] also succeeded in the
derivation of hiPSC from a CB-derived CD133+ cell subset which
contains hematopoietic progenitor cells committed to myeloid but
not lymphoid lineages [12,13,14,15]. Furthermore, Takenaka et al
[16] very recently derived hiPSC from CB-derived CD34+ cells
upon retroviral over-expression of OKSM factors and showed that
further p53 depletion robustly enhanced reprogramming efficien-
cy. Finally, Ye et al [17] also derived hiPSC from blood cells and
CB-derived CD34+ cells using four independent retroviral vectors:
pMXs-Oct4, pMXs-Sox2, pMXs-Klf4 and pMXs-c-myc.
Despite these advances, to the best of our knowledge, hiPSC
have not been generated yet from CB-derived primitive CD34+
cells using a single polycistronic lentiviral vector based on 2A and
IRES sequences expressing the four reprogramming factors
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the number of proviral insertions. In addition, even though
important information is available in the mouse [20,21], it has not
been robustly assayed in humans whether the cellular origin
influences the in vitro differentiation potential of hiPSC lines. That
is, whether those hiPSC derived from a certain somatic cell type
are more prone to differentiate towards the same specific lineage
from which they were initially derived, or on the contrary, hiPSC
lines derived from different cell types differentiate equally towards
certain lineage, regardless of the origin of the reprogrammed
somatic cell.
Here, we describe the successful derivation of hiPSC from CB-
CD34+ cells using a single polycistronic lentiviral vector expressing
OKSM based on 2A and IRES sequences [18,19]. Interestingly,
the ectopic expression of OKSM was fully silenced upon
reprogramming in some hiPSC clones while other hiPSC clones
failed to silence the transgenes expression. The inability/ability of
hiPSC to silence the reprogramming factors was not associated to
the cell type/tissue origin. However, continued transgene
expression seriously impaired hematopoietic and early neuroecto-
derm differentiation potential, indicating that residual expression
of the reprogramming factors compromises hiPSC differentiation.
This was confirmed in transgene-free hiPSC clones generated
from CB CD34+ hiPSC with residual transgene expression by
Cre-mediated excision of the provirus cassette, which resulted in
significantly improved differentiation capacity.
Materials and Methods
CB collection and CD34+ cell isolation
Umbilical CB samples from healthy newborns were obtained
from the Andalusian Public Cord Blood Bank upon approval by
our local (University of Granada) Ethics and Biozahard Board
Committee (ABR/JFJ/S-23). All human samples were obtained
upon informed consent given by the parents. Mononuclear cells
were isolated using Ficoll-Hypaque (GE Healthcare, Stockholm,
Sweden). After lysing the red blood cells (Lysis solution, StemCell
Technologies, Vancouver, Canada), CD34
+ cells were purified by
magnetic bead separation using the human CD34 MicroBead kit
(Miltenyi, Munich, Germany) and the AutoMACS Pro separator
(Miltenyi) as per manufacturer’s instructions [22,23]. Post sorting
purity was higher than 95% (data not shown). After washing in
phosphate-buffered saline (PBS), CD34
+ cells were plated in liquid
culture: Stem Span medium (Stem Cell Technologies) supple-
mented with SCF (100 ng/mL), FLT3L (100 ng/mL) and IL-3
(10 ng/mL) (Peprotech, London, UK) [23,24]. Furthermore, early
passage (p5–p10) human embryonic fibroblasts (HEFs) obtained
from ATCC (IMR90) were used and grown in DMEM+10% FBS
[25].
Vectors, lentiviral production and transduction of
fibroblasts and CB-derived CD34+ hematopoietic stem/
progenitor cells (HSPC)
CB-derived CD34+ HSPCs (1610
5 cells/mL) were pre-
stimulated for 48 h in Stem Span medium supplemented with
SCF (100 ng/mL), FLT3L (100 ng/mL) and IL-3 (10 ng/mL) in
fibronectin-coated plates (Becton Dickinson, San Jose ´, CA). hiPSC
were generated by infection of either pre-stimulated CD34+
HSPCs or fibroblasts with high-titer (MOI=20–30) policistronic
lentiviral vectors co-expressing the four human reprogramming
factors Oct4, Klf4, Sox2 and c-myc (OKSM) under the
constitutive promoter (EF1a) using 2A and IRES elements as
shown in Figure 1A. Viral particles pseudotyped with the VSV-G
protein were generated on 293T cells (purchased from the ATCC;
www.atcc.org) using a standard calcium-phosphate transfection
protocol and were concentrated by ultracentrifugation [24,26,27].
Cells were infected overnight and the following day the viral
supernatant was removed and transduced fibroblast or CD34+
HSPCs were washed and allowed to expand for 3 days before
transferring them onto irradiated (4000 cGy) feeders (MEFs).
Once transferred onto feeders, the cultures were maintained in
KO-DMEM supplemented with 20% serum replacement, 1%
nonessential amino acids, 1 mM L-glutamine, and 0.1 mM b-
mercaptoethanol (all from Invitrogen) and 50 ng/mL of basic
fibroblast growth factor (bFGF) (Miltenyi). Identification of the
first emerging hiPSC colonies (10–15 days after viral infection) and
passage onto fresh feeders was done as previously described
(Figure 1B) [6,25]. Approval from the Spanish National
Pluripotent Ethical Committee was obtained to work with hiPSC
(ABR/JFJ/S-23).
Total RNA purification and Reverse-Transcriptase-
Polimerase Chain Reaction (RT-PCR)
Total RNA extraction and RT-PCR reactions were done as
previously described [28]. Briefly, total RNA was extracted from
hiPSC or differentiating embryoid bodies (hEBs) using Total RNA
Purification Kit (Norgen, Canada). First-strand cDNA synthesis was
performed using the First-Strand cDNA Synthesis Kit (Amersham)
and the expression of pluripotency-associated transcription factors
(Oct-4,Nanog, Rex-1and Sox2)and earlymesoderm andectoderm
factors(Brachyuryand Pax6,respectively)wasassessedbyend-point
RT-PCR as described [28]. GAPDH was used as a housekeeping
gene. The following PCR conditions were used: 5 min at 94uC, 35
cycles of 30 seconds at 94uC followed by 50 seconds at 60uCa n d
50 seconds at 72uC and a final extension of 10 min at 72uC. The
PCR products were resolved in 1% agarose gel. Primer sequences
were as follows: Oct3/4: 59-TCTGCAGAAAGAACTCGAG-
CAA-39,a n d5 9-AGATGGTCGTTTGGCTGAACAC-39; Na-
nog: 59-TGCAGTTCCAGCCAAATTCTC-39,a n d5 9-CCTA-
GTGGTCTGCTGTATTACATTAAGG-39; Sox-2: 59-CCCC-
CGGCGGCAATAGCA-39, and 59-TCGGCGCCGGGGAGAT-
ACAT-39; Rex-1: 59-CAGATCCTAAACAGCTCGCAGAAT-39,
and 59-GCGTACGCAAATTAAAGTCCAGA-39; Brachyury: 59-
ATGAGCCTCGAATCCACATAGT-39 and 59-TCCTCGT-
TCTGATAAGCAGTCA-39; Pax6: 5-CCGGCAGAAGATTG-
TAGAGC-3 and 5-CGTTGGACACGTTTTGATTG-3 and G-
APDH: 59-GAAGGTGAAGGTCGGAGTC-39, and 59-GAA-
GATGGTGATGGGATTTC-39.
In order to detect the expression/silencing of the reprogram-
ming factors encoded from the lentiviral vector, the following
primers were used: Forward (on Oct-4): 59-GCCTTTCC-
CCCTGTCTCCGTC-39 and Reverse (on Klf-4) 59-GGC-
TCCGCCGCTCTCCAGGTCTG-39. The PCR conditions were
as follows: 2 min at 95uC, 40 cycles of 30 s at 94uC followed by
30 s at 60uC and 60 s at 72uC, and a final extension of 5 min at
72uC.
Embryoid body (EB) formation and in vitro differentiation
Human iPSC were harvested, transferred to low-attachment
plates and allowed to differentiate spontaneously through EB
formation in KO-DMEM supplemented with 20% FBS (Invitro-
gen), 1% L-glutamine, 0.1 mM non-essential amino acids and
0.1 mM b-mercaptoethanol but without bFGF with media
changes every 4 days. For spontaneous differentiation, day 21
EBs were spun down, fixed with 4% paraformaldehyde for
10 minutes and embedded in paraffin and sections were stained
with hematoxylin and eosin (H&E) [29,30,31]. For each staining,
OKSM Residual Expression and iPSC Differentiation
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35824three sections per specimen were taken. Immunostaining for
lineage-specific markers was performed as described below.
Teratoma formation
Animal protocols were approved by the Granada University
Hospital Council On Animal Care and Experimentation (CEEA-
2011-361). In vivo pluripotency was tested as previously described
[31]. In brief, hiPSC lines were harvested with Collagenase IV.
hiPSC were implanted beneath the testicular capsule of a young
(6–8 weeks) NOD/SCID IL2Rc
2/2 male mouse (The Jackson
Lab, Bar Harbor, MA). Teratoma growth was determined by
palpation every week, and the mice were sacrificed 7–10 weeks
after implantation. Teratomas were fixed, embedded in paraffin
and sections were stained with H&E. Immunostainings for germ-
layer specific markers were performed as described below.
Immunocytochemistry
EB and teratoma sections were incubated (1 hour at room
temperature) with primary antibodies for anti-bIII-tubulin
(DAKO; 1:100), pan-cytokeratin (DAKO; 1:100) and anti-smooth
muscle actin (Chemicon; 1:100). Then, the sections were
incubated with a biotinylated secondary antibody (30 minutes at
room temperature) and a streptavidin peroxidase complex
(30 minutes at room temperature) (Vector Laboratories Inc).
The immunostaining was visualized using diaminobenzidine and
counterstained with H&E. The washing steps were done in PBS.
Negative controls were prepared by replacing the primary
antibody by PBS.
Flow Cytometry
Expression of pluripotency-associated markers in established
hiPSC was determined by flow cytometry using antibodies against
SSEA-3, SSEA-4 (Developmental Studies Hybridoma Bank,
University of Iowa, USA), TRA-1-60 and TRA-1-81 (Chemicon,
CA) and Oct-4 (Pharmigen). An irrelevant isotype-match antibody
was always used. Tripsin-dissociated hiPSC lines were suspended
in PBS+3%FBS at a concentration of 2–5610
4 cells per 100 mL
and incubated with the specific primary antibody for 30 minutes
at 4uC. After washing with PBS+3%FBS, cells were incubated
with 2.5 mL of FITC- or PE-conjugated goat anti-mouse IgG
antibody (Immunotech, Marseille, France). After 15 minutes at
RT, the cells were washed and stained with 7-aminoactinomycin
D (7-AAD) (Immunotech) for 5 minutes at RT. Live cells
identified by 7-AAD exclusion were analyzed for expression of
Figure 1. Lentiviral vector design and experimental strategy used in the generation of hiPSC from CB-derived CD34+ HSPCs. (A)
Structure of the policistronic lentivector used for iPSC generation. EF1a is the constitutive promoter. The four reprogramming factors (Oct4, Klf4,
Sox2, c-myc; OKSM) are expressed as independent transcripts through the 2A and IRES sequences. The small blue arrows identify the primers used to
determine the silencing of the ectopic expression of the reprogramming factors. (B) Timeline of fibroblast and CB-CD34+ reprogramming. CD34+
cells were MACS-isolated and pre-stimulated with hematopoietic cytokines. Two days later, CB-CD34+ cells were infected. After 3 days, infected cells
were transferred onto feeders. Small adherent colonies were observed around day 8–9. hESC-like colonies were identifiable after 10–15 days.
doi:10.1371/journal.pone.0035824.g001
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FACSCanto-II flow cytometer equipped with FACSDiva software
(Becton Dickinson) [32,33].
G-Banding
Karyotype analysis was performed according to previous
standardized protocols [34,35,36]. At least 20 metaphases of each
sample were counted.
Cre-mediated excision of the reprogramming factors in
hiPSC
Transgene-free hiPSC were generated by excision of the LoxP-
flanked sequences by infection of hiPSC with adenoviral vectors
expressing the Cre-recombinase gene under the control of the
CMV promoter (Ad-CMV-Cre), as previously described [37]. The
successful gene knockdown and generation of transgene-free
hiPSC after the excision of the LoxP regions was confirmed by
Figure 2. Characterization of hiPSC generated either from fibroblasts or CB-CD34+ HSPCs. All the hiPSC lines generated from either
fibroblasts or CB-CD34+ HSPCs express the pluripotency markers Oct4, Sox2, Nanog and Rex1 (A), the pluripotent surface markers Tra-1-60, Tra-1-81,
SSEA-3 and SSEA-4, as well as nuclear Oct4 (B) and display an euploid karyotype (C). All hiPSC lines differentiated in vivo (teratoma formation) (D) into
tissues representing the three germ layers: ecto-, meso- and endoderm. Immunocytochemistry pictures are shown at 206magnification. (E) RT-PCR
confirming that CB-iPSC#2 and F-iPSC#2 did not silence OKSM factors after .20 passages.
doi:10.1371/journal.pone.0035824.g002
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hematopoietic and neural differentiation protocol from hiPSC and endpoint analyses. Right panel: representative flow cytometry dot plots displaying
OKSM Residual Expression and iPSC Differentiation
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hiPSC and hEBs using the DNAeasy kit (Qiagen, Alameda, CA).
200 ng of DNA were used for each PCR reaction. The PCR
conditions were as follows: 2 min at 95uC, 40 cycles of 30 s at
94uC followed by 30 s at 60uC and 60 s at 72uC, and a final
extension of 5 min at 72uC. The following primers were used:
Forward: 59-GCCTTTCCCCCTGTCTCCGTC-39 and Reverse
59-GGCTCCGCCGCTCTCCAGGTCTG-39.
hiPSC differentiation towards hematopoietic lineage
At confluence, hiPSC maintained feeder-free were treated with
collagenase IV and scraped off of the Matrigel attachments using a
pipette. They were then transferred to low-attachment plates
(Corning, NY) to allow hEB formation (iPSC colonies cannot
attach any longer in low-attachment plates and form this
differentiating structures termed EBs) by overnight incubation in
differentiation medium consisting of KO-DMEM supplemented
with 20% non-heat-inactivated FBS, 1% nonessential amino acids,
1 mM L-glutamine, and 0.1 mM b-mercaptoethanol and without
bFGF. The medium was changed the next day (day 1) with the
same differentiation medium supplemented with hematopoietic
cytokines [300 ng/mL SCF, 300 ng/mL Flt-3 ligand, 10 ng/mL
IL-3, 10 ng/mL IL-6, and 50 ng/mL G-CSF and 25 ng/mL
BMP-4] [22,38,39,40]. EBs were dissociated using collagenase B
(Roche Diagnostic, ON, Canada) for 2 hours at 37uC followed by
10 minutes incubation at 37uC with enzyme-free Cell Dissociation
Buffer (Invitrogen) at day 15 and 22 of development. Single cell
suspension was obtained by gentle pipetting and passage through a
70-mm cell strainer (Becton Dickinson) and the dissociated cells
were stained with anti-CD34-FITC and anti-CD45-APC (Milte-
nyi) antibodies and 7AAD. Live cells identified by 7-AAD
exclusion were analyzed using a FACSCanto II flow cytometer
equipped with FACSDiva software (Becton Dickinson). Primitive
and total blood cells were identified as CD45+CD34+ and
CD45+CD342, respectively [41,42,43,44].
Colony Forming Unit (CFU) formation
Human clonogenic progenitor assays were performed by plating
1000 cells from day 15 hEBs into methylcellulose H4230 (Stem
Cell Technologies) supplemented with recombinant human
growth factors: 50 ng/mL SCF, 3 units/mL erythropoietin,
10 ng/mL GM-CSF, and 10 ng/mL IL-3. Cells were incubated
at 37uC in a 5% CO2 humidified atmosphere and colonies
counted at day 14 of CFU assay using standard morphological
criteria [45,46]. CFUs were harvested from the methylcellulose,
dissociated in cold PBS, washed in PBS and stained with anti-
CD15-FITC, anti-CD33-PE and anti-CD45-APC (Becton Dick-
inson) for flow cytometry phenotyping
Early neural differentiation
For neural differentiation, the protocol was slightly modified
from that described by Pankratz et al [47]. Briefly, hiPSC lines
were grown in suspension as hEBs in growth medium for 4 days.
The hEBs were then cultured in neural medium composed by
Dulbecco’s modified Eagle’s medium/F12, nonessential amino
acids, 2 mg/mL heparin, and the neural cell supplement N2
(Gibco, Billings, MT) for 3 additional days. Early neural
differentiation was evaluated at day 8 of culture by dissociating
and staining hEBs single cells with the neural embryonic antigen
A2B5 using a mouse anti-human A2B5 (1:25 dilution; Miltenyi) or
the corresponding isotype control. The secondary antibody was a
FITC-conjugated goat anti-mouse antibody.
Results
Reprogramming CB-CD34+ HSPCs with OKSM factors
using a single policistronic lentivector containing 2A and
IRES sequences
The majority of HSPCs are quiescent under physiological
conditions [48]. Because integration and expression of retroviral
constructs requires mitotic division of target cells, we aimed at
generating hiPSC using lentiviral vectors which are capable of
infecting both quiescent and cycling cells [48]. In order to
reprogram CB-CD34+ HSPCs to pluripotency using a single
policistronic lentiviral vector driving the expression of OKSM
under the constitutive EF1a promoter (Figure 1A), 1610
5
cytokine pre-stimulated CD34+ HSPCs were infected overnight
with high-titer concentrated viral supernatant. After 16 hours, the
virus-containing media was washed away and the infected cells
were allowed to expand and recover for two further days. Three
days after infection, CB-CD34+ cells were transferred onto
irradiated feeders and cultured in hESC typical culture medium
(Figure 1B). As early as 8–9 days after postinfection tiny colonies
started to appear in CD34+ cultures transduced with OKSM
lentiviruses (Figure 1B). At 10–15 days post-infection, we found
that some of these initial small colonies were transient and they
disappeared, likely indicating that they constituted partially
reprogrammed iPSC (pseudo-iPSC) unable to survive and expand
over passages [49,50]. However, other colonies expanded and
exhibited typical hESC morphology with sharp borders, and were
comprised of small, tightly packed cells with large nuclei
(Figure 1B). Overall, 21 small colonies (pseudo-iPSC) were
obtained from 1610
5 infected CD34+ HSPCs (transient repro-
gramming efficiency of 1:4761 CD34+ cells; 0.02%). Nevertheless,
the reprogramming efficiency, as judged by the number of fully
reprogrammed iPSC was of 1 iPSC: 50.000 CD34+ cells, resulting
in a 0.0002% reprogramming efficiency.
In vitro and in vivo characterization of the fibroblast and
CB-CD34+ hiPSC lines
Two hiPSC clones were generated from fibroblasts (termed F-
iPSC #1 and F-iPSC #2) [25] and other two from CB-CD34+
HSPCs (termed CB-iPSC#1 and CB-iPSC#2). All hiPSC have
been equally cultured for over 20 passages in feeder-free
conditions using matrigel and conditioned media and have
successfully survived repetitive freeze-thaw processes (data not
shown). In addition, all hiPSC lines expressed the ESC-associated
transcription factors Oct-4, Nanog, Rex-1 and Sox-2 (Figure 2A),
and the pluripotency-associated surface markers Tra-1-60, Tra-1-
81, SSEA-3, SSEA-4 and nuclear Oct-4 (Figure 2B). Important-
ly, after 20 passages, they all remained karyotypically euploid
(Figure 2C).
Functionally, these hiPSC lines successfully differentiated in vitro
through EB formation into tissues representing the three germ
how primitive hematopoietic cells (CD45+CD34+), mature hematopoietic cells (CD45+) and cells committed towards early neuroectoderm (A2B5+)
are identified and analyzed. (B–E) Lines CB-hiPSC #2 and F-hiPSC #2 display a significant impairment in their differentiation capacity into primitive
blood cells (CD45+CD34+)( B), total blood cells (CD45+CD342)( C), colony-forming unit potential (D) and early neural progenitors (E). (F) The
expression of the reprogramming factors remain upon hematopoietic (H) and neural (N) differentiation, consistent with that observed in
undifferentiated hiPSC lines.
doi:10.1371/journal.pone.0035824.g003
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actin+ cells) and endoderm (pan-cytokeratin+ cells) (Figure S1). In
vivo, all hiPSC lines formed teratomas ,6 to 8 weeks after
inoculation [31]. These complex and disorganized tumours
contained a variety of tissues representing the three germ layers
(Figure 2D), demonstrating the pluripotent features of these
hiPSC lines.
Figure 4. Transgene-free hiPSC clones display improved differentiation capacity. (A) PCR of genomic DNA (gDNA) showing successful
adenovirus-based Cre-excision of the reprogramming cassette in CB-hiPSC. CB-hiPSC #2 after Cre-excision significantly improved its differentiation
capacity into early neural progenitors (B) total blood cells (C) and colony-forming unit potential (D). Flow cytometry from CB-hiPSC #2 CFUs before
and after Cre excision clearly shows that CD45+ and CD45+CD33+ myeloid cells appear in CFUs from CB-hiPSC #2 after Cre excision. (E) RT-PCR
confirming that in CB-hiPSC #2 after Cre-excision the expression of ectopic reprogramming factors is greatly reduced in undifferentiated hiPSC and
after 15 days of hematopoietic and neural differentiation. (F) Q-RT-PCR showing an increased expression of the early differentiation markers, PAX6
(neural) and Brachyury (mesendoderm), in CB-iPSC #2 after Cre-mediated OKSM excision. Q-RT-PCR expression is normalized against GAPDH.
doi:10.1371/journal.pone.0035824.g004
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reprogramming. Unexpectedly, we found that two hiPSC lines
(CB-iPSC#1 and F-iPSC#1) fully silenced the reprogramming
transgenes whereas the other two hiPSC lines (CB-iPSC#2 and F-
iPSC#2) failed to silence the transgene expression over a period of
20 passages (Figure 2E). Of note, the inability of the different
hiPSC to silence the reprogramming factors was not associated to
the cell type/tissue origin (fibroblasts versus CB-CD34+ HSPCs).
Residual transgene expression prevents hematopoietic
and neuroectoderm differentiation of hiPSC
In order to assess whether hiPSC derived from CD34+ HSPCs
are better able to generate hematopoietic cells than hiPSC derived
from fibroblasts [51] (the so-called ‘‘epigenetic memory’’) and
whether the residual expression of the reprogramming factors
affects hiPSC directed differentiation, we have compared side-by-
side the hematopoietic and early neuroectoderm developmental
potential of the four hiPSC generated: two CB-iPSC and two F-
iPSC. Human iPSC were allowed to differentiate in vitro into blood
or early neuroectoderm by EB formation as described [42,52].
The emergence of primitive blood cells (identified as
CD45+CD34+) and total blood cells (CD45+CD342) was
analyzed at day 15 and 22 of development (Figure 3A). The
presence of hematopoietic progenitors with CFU potential was
analyzed at day 15 of EB development (Figure 3A). Early
neuroectoderm cells (identified as A2B5+) were analyzed at day 8
of EB development (Figure 3A).
Interestingly, as shown in Figure 3B, C, D, E, those hiPSC
which had silenced OKSM ectopic expression (CB-iPSC#1 and
F-iPSC#1) displayed fair hematopoietic (,30% CD45+) and early
neuroectoderm (,40% A2B5+) differentiation potential. In
contrast, those hiPSC which failed to switch off OKSM expression
(CB-iPSC#2 and F-iPSC#2) were unable to differentiate towards
either lineage (,1% CD45+ and ,3% A2B5+), regardless of the
source of the reprogrammed cell. The expression of the ectopic
reprogramming factors remained upon hematopoietic and neural
differentiation, consistent with that observed in undifferentiated
hiPSC (Figure 3F). This indicates that the residual expression of
the reprogramming factors seriously compromise hiPSC differen-
tiation. Additionally, although no differences in the neuroecto-
derm differentiation potential were observed, the CB-iPSC#1 line
displayed a much more efficient hematopoietic differentiation
(primitive and total blood cells and CFU) than F-iPSC#1,
indicative of epigenetic memory.
Transgene-free hiPSC clones display improved
differentiation capacity
To confirm that the residual expression of the reprogramming
factors compromises hiPSC differentiation, we took advantage of
the LoxP sites flanking the expression cassette (OKSM) to excise
the OKSM transgene by infection of CB-iPSC#1 (transgene
silenced) and CB-iPSC#2 (transgene not silenced) with adenoviral
vectors expressing the Cre-recombinase gene under the control of
the CMV promoter (Ad-CMV-Cre) [37]. Successful Cre-mediated
excision of the OKSM transgene was confirmed by genomic PCR
in both CB-iPSC#1 and CB-iPSC#2( Figure 4A). Cre-mediated
removal of OKSM did not affect either hiPSC homeostasis or the
expression of pluripotency-associated surface markers and tran-
scription factors (Figure S2). After Cre-mediated excision of the
non-silenced OKSM transgene, the CB-iPSC#2 line significantly
improved its differentiation capacity into early neural progenitors
(5-fold increase; Figure 4B) total blood cells (4-fold increase;
Figure 4C) and CFU progenitor potential (40-fold increase;
Figure 4D). The abolishment of OKSM expression after Cre-
mediated excision was maintained long-term upon hematopoietic
and neural differentiation (Figure 4E). As expected, differentia-
tion was not improved in CB-iPSC#1 infected with Ad-CMV-Cre
because the OKSM transgene was already switched off in this
hiPSC line (Figure 4B,C). In agreement with the significantly
higher functional/phenotypic neural and blood differentiation, a
robust increase in the expression of the early neural- and
mesoderm-specific transcription factors Pax6 and Brachyury,
respectively, was observed in the CB-iPSC#2 line after Cre-
mediated OKSM removal (Figure 4F). In contrast, the expression
of the pluripotency factor Oct4 dropped faster in the CB-iPSC#2
line after OKSM excision, suggesting that the residual expression
of the reprogramming factors functions as a developmental brake
impairing hiPSC differentiation.
Discussion
Induced PSCs have been generated from different somatic cell
types and recently also from various cell populations of CB
[7,11,16,17]. There is some controversy, not yet rigorously
resolved in the human context, that the more immature the
somatic cell to be reprogrammed, the easier and more efficient
hiPSC generation is [51,53]. If this hypothesis is confirmed, CB
may represent an advantageous cell source for hiPSC generation,
given that it contains more immature and cytokine-responsive
subsets of HSPCs [12,13,51]. CB also represents a source enriched
with hematopoietic, mesenchymal and endothelial progenitors.
Importantly, CB cells are young newborn cells expected to
accumulate minimal somatic mutations compared to other
somatic tissues sourced from older subjects, and they display the
immunological immaturity of neonatal tissues. Here, we report the
successful derivation of fully-characterized hiPSC lines from CB-
CD34+ cells. In contrast to Giorgetti et al [7], we generated hiPSC
from CD34+ cells rather than from the CD133+ cell subset
because the latter contains hematopoietic progenitor cells already
committed to myeloid but not lymphoid lineages- [12,13,14,15]. It
is worth mentioning that Takenaka et al [16] succeeded very
recently in the derivation of hiPSC from CB-derived CD34+ cells
upon OKSM ectopic expression combined with the deletion of the
p53 gene; in the presence of p53 they were unable to maintain the
hiPSC longer than 1 month. Our data, however, reveals the
successful generation and maintenance of hiPSC from CB-CD34+
cells harbouring wild-type alleles for p53. The differences between
these two studies may be explained by the use of distinct
hematopoietic cytokines, distinct viral transduction systems (retro
versus lenti) as well as the use of different feeders (MEFs versus SNLs)
and culture conditions.
To date, hiPSC have been generated from CB-CD34+ HSPCs
using four independent retroviral vectors (pMX) expressing
OKSM or upon deletion of the p53 gene. However, we succeeded
in the generation of fully-characterized hiPSC from newborn
CD34+ HSPCs using a single excisable polycistronic lentiviral
vector based on 2A and IRES sequences expressing OKSM under
the EF1a constitutive promoter, likely minimizing the number of
proviral insertions. Interestingly, although it has been shown that
hiPSC can be generated from cryopreserved CB, this is the first
report showing successful derivation of hiPSC from fresh CB-
CD34+ cells [16,17]. Our data indicate that cryopreserved and
fresh CB units compare quite well in terms of hiPSC derivation
efficiency and karyotypic stability. Our hiPSC remain karyotyp-
ically stable after 30 passages and the hiPSC derivation efficiency
was 0.0002% which is low but within the reported range of iPSC
derivation efficiency (0.0001%–0.5%) [54,55], suggesting that
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stochastic events over several days that eventually induces a very
small fraction of cells to acquire a stable pluripotent state. The
slow reprogramming process coupled to the low reprogramming
efficiency impedes detailed mechanistic studies of this technology
[55,56]. The identification of small molecules capable of
enhancing the reprogramming efficiency is an active field of
research. Indeed, recent studies have demonstrated that several
compounds which have the capacity to modulate epigenetic-
modifying enzymes exhibit positive effects on iPSC generation. For
instance, treatment with the DNA methyltransferase 5-AZA and
with the histone deacetylase inhibitors valproic acid, sodium
butyrate or trichostatin A were capable of increasing the
reprogramming efficiency [55,56,57].
Several studies have demonstrated that reactivation or sustained
expression of reprogramming factors may result in deleterious
outcomes such as tumor formation or disruption of pluripotency
[58,59,60]. Moreover, the study of the biology of reprogramming
and the evaluation of how closely iPSC and ESCs functionally
resemble each other will greatly benefit from the use of
homogeneous populations devoid of any residual transgene
expression. We found that the ectopic expression of OKSM was
fully silenced upon reprogramming in some hiPSC and was not
reactivated upon differentiation, whereas other hiPSC failed to
silence the transgene expression. The inability of some hiPSC to
silence the reprogramming factors was associated to neither the
cell type/tissue origin nor lentiviral backbone/promoters used.
Integrating viral delivery methods (lenti- or retro-vectors) do insert
the exogenous DNA randomly in the genome. Epigenetic
remodelling and marks (i.e. promoter methylation or histone
acethylation) vary throughout the genome leaving genomic slots
refractory to ectopic gene expression whereas other parts of the
host genome may be much less reluctant to ectopic gene
expression [46,61,62]. It may thus be speculated that the level of
epigenetic control dictated by the integration site within the host
genome may explain why some iPSC clones fully silence the
transgese but other iPSC clones do not.. We have compared side-
by-side the hematopoietic and early neuroectoderm developmen-
tal potential of all hiPSC and we found that residual expression of
the reprogramming factors functions as a developmental brake
impairing hiPSC differentiation towards both hematopoietic and
neuroectoderm lineages. Taking advantage of a floxed single copy
of a policistronic reprogramming vector, we excised the repro-
gramming cassette using Ad-CMV-Cre and ‘‘transgene-free’’ CB-
hiPSC were generated. Cre-mediated removal of OKSM did not
affect either hiPSC homeostasis or the expression of pluripotency-
associated surface markers and transcription factors. After Cre-
mediated excision of the non-silenced OKSM transgene, CB-iPSC
significantly improved the differentiation capacity into both
hematopoietic cells (mesoderm) and early neural progenitors
(ectoderm). Our findings emphasize the importance of vector
excision prior to directed differentiation of CB-iPSC in culture if
the goal is to adapt differentiation culture conditions originally
developed in hESC culture systems. This is crucial not only for
potential cell replacement strategies but also for drug-screening
and disease modeling applications in which CB-iPSC may
represent the healthy controls for hiPSC generated from a variety
of primary patient leukemic blasts. Nevertheless, our findings do
not prove that ‘‘transgene-free’’ CB-iPSC are functionally
equivalent to hESCs in terms of differentiation capacity. Despite
transgene-silenced and transgene-removed CB-iPSC performed
well in neuroectoderm and blood-promoting culture conditions,
further extensive inter-laboratory studies must be prospectively
undertaken comparing the lineage-specific differentiation potential
and epigenetic memory among multiple hiPSC derived from
different tissues, and using distinct strategies and hESCs. In
summary, we report for the first time the generation of hiPSC
from fresh CB-derived CD34+ HSPCs using a single excisable
polycistronic (OKSM) lentiviral vector. A direct comparison
between hiPSC clones before and after Cre-mediated reprogram-
ming excision reveals that residual expression of the reprogram-
ming factors robustly prevents both mesoderm and neuroectoderm
differentiation.
Supporting Information
Figure S1 hiPSC lines display in vitro potential for three
germ layer differentiation. Histological analysis of EBs
showing spontaneous in vitro differentiation into ectoderm (pan-
cytokeratin+), mesoderm (smooth muscle Actin+) and endoderm
(neuroephitelium).
(TIF)
Figure S2 Phenotypic and molecular characterization of
CB-iPSC after Cre-mediated excision of the reprogram-
ming transgenes. After Cre-mediated excision of the repro-
gramming transgene, the CB-iPSC express the pluripotent surface
markers SSEA-3, SSEA-4, Tra-1-60 and Tra-1-81 as well as
nuclear Oct4 by flow cytometry (A) and retain expression of the
pluripotency markers Oct4, Sox2, Nanog and Rex1 by RT-PCR
(B).
(TIF)
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